Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines. 

duración terapia de doble antiagregación plaquetaria

Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to DAPT duration. 

Researchers calculated risk ratios of major or life‐threatening bleeding, stroke, and all‐cause mortality. 

Studies using oral anticoagulants and antiplatelet therapy concomitantly, such as those on atrial fibrillation, were excluded. 

It included four randomized controlled trials, 2 propensity‐score matched studies, and 1 observational study, with a total 2498 patients.

1249 received monotherapy, 485 received DAPT for 3 months and 764 received DAPT for 6 months. All these studies used aspirin as monotherapy. 


Read also: CT and Angiography Agreement in Patients from the ISCHEMIA Trial.


The analysis showed that aspirin monotherapy significantly reduced the risk of life-threatening bleeding vs. 3-month DAPT (RR=2.13, p=0.016) and 6-month DAPT (RR=2.54, p=0.007).

There were no differences when comparing 3-month vs 6-month DAPT.

Stroke and mortality rates were similar across groups. 


Read also: Cerebral Protection Devices during TAVR in the Daily Practice.


Clinical guidelines indicating post TAVR DAPT await updating after several studies, and more recently, a meta-analysis with consistent results in favor of monotherapy. 

Conclusion

Aspirin monotherapy after TAVR reduced the risk of bleeding and did not increase stroke or mortality rate vs. 3- and 6-month DAPT. 

JAHA-120-019490free

Original Title: Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta-Analysis.

Reference: Toshiki Kuno et al. J Am Heart Assoc. 2021;10:e019490.  DOI: 10.1161/JAHA.120.019490.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...